Stay updated on Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial
Sign up to get notified when there's something new on the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page.

Latest updates to the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page
- Check5 days agoChange DetectedA new entry Revision: v3.3.3 was added to the history, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 were removed from the footer.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedNew revision entry v3.3.2 appears in Study Record Versions, and v3.2.0 is no longer listed. The updates reflect revision history and QC status details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedThe top government funding notice banner has been removed, and the study record content remains unaffected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check63 days agoChange DetectedRoutine version updates are shown in the record history and do not modify the core trial details; no new information affecting eligibility, interventions, or outcomes is introduced, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check85 days agoChange DetectedCore content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.SummaryDifference12%

- Check92 days agoChange Detected- The page now shows Revision: v3.1.0, replacing the previous v3.0.2.SummaryDifference0.3%

Stay in the know with updates to Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page.